Strikingly, TSLPR-/- mice treated with anti-IL-7R displayed even lower clinical arthritis scores compared to the anti-IL-7R treated WT mice and the PBS treated TSLPR-/- mice (18.7 ± 3.6, p = 0.003), though there was no statistically significant difference between anti-IL-7R treated TSLPR-/- mice and the anti-IL-7R treated WT mice or PBS treated TSLPR-/- mice (Fig 1A). Here, IL7R is linked to arthritic joint disease.